openPR Logo
Press release

Alzheimers Disease Biomarkers Market Report 2018-2026 | NanoSomix, Inc., Fujirebio, Imagilys SPRL, Merck KGaA, Enzo Life Sciences

Alzheimers Disease Biomarkers Market Report 2018-2026 |

"The Latest Research Report Alzheimers Disease Biomarkers Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2018 - 2026 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz"

Alzheimer’s disease is an irreversible neural disease that progresses with age. Alzheimer’s disease is characterized by degeneration of brain cells i.e., neurons, which leads to loss of memory and other important functions controlled by the central nervous system (CNS). Symptoms of the disease are memory loss and mild confusion, often termed as dementia. These symptoms are visible in patients aged 50 to 60 years. Alzheimer’s is considered to be caused by a combination of genetic, environmental, and lifestyle induced factors. Alzheimer’s disease is mostly diagnosed among the patients who are having symptoms similar to Alzheimer’s disease such as memory loss, dementia, etc., it is often post-onset of the disease. Till recently, there were no tests or tools to pre-diagnose this disease or to check the susceptibility of a patient for Alzheimer’s disease.

Standard diagnosis protocol for diagnosing Alzheimer’s disease was limited to subjective tests on memory, problem solving, behavior, and personality. Correlation of past medical problems and family history of Alzheimer’s disease are also taken into consideration for diagnosis. Physicians also perform various imaging tests such as computed tomography (CT), magnetic resonance imaging (MRI), or positron emission tomography (PET). These tests may be repeated to confirm the disease; however, Alzheimer’s disease can be conclusively confirmed only after death of a patient through autopsy of the brain tissue and linking it with clinical findings. In April 2017, the U.S. FDA approved 23andMe, Inc. to offer a genetic test for pre-diagnosis of Alzheimer’s disease directly to customers. Similarly, in February 2018, researchers at Japan-based Shimadzu Corporation announced that they have developed blood test for prediction of onset of Alzheimer’s disease based on detection of amyloid beta (A?) deposits. Technical advancements in diagnostic tests and tools for Alzheimer’s disease are projected to propel the global Alzheimer’s disease biomarkers market. However, accessibility of these tests and tools and estimated high cost of procedures are likely to hamper the market during the forecast period.

Get Sample Copy of this report @ https://www.marketresearchreports.biz/sample/sample/8249

Alzheimer’s disease can be diagnosed using specific biomarkers such as peptides and genes. These biomarkers play an important role in predictive and confirmatory diagnosis of Alzheimer’s disease. The global Alzheimer’s disease biomarkers market can be segmented based on type of biomarker, detection technique, end-user, and region. In terms of type of biomarker, the market can be classified into peptide-based, gene-based, imaging biomarkers, and others. The peptide-based segment can be categorized into beta amyloid-based, tau protein-based, and others. The gene-based segment can be divided into apolipoprotein E-based, amyloid precursor protein & presenilin-based, and others. Among these, gene-based biomarkers are likely to be more accurate. Increase in demand for molecular diagnostics such as PCR is projected to spur adoption of these biomarkers. Based on detection technique, the global Alzheimer’s disease biomarkers market can be segmented into polymerase chain reaction (PCR), enzyme linked immunoassay (ELISA), and radiology imaging such as CT, MRI, and PET scan. Major end-users of Alzheimer’s disease biomarkers are hospitals & clinics, independent diagnostic laboratories, and others.

In terms of region, the global Alzheimer’s disease biomarkers market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. High adoption of technically advanced diagnostic tools and better reimbursement support in the U.S. are projected to boost the Alzheimer’s disease biomarkers market in North America during the forecast period. A report published by Alzheimer’s Disease International stated that an estimated 10.5 million people in Europe and 22.9 million in Asia Pacific were reported to have Alzheimer’s disease in 2015. High prevalence of Alzheimer’s disease in these regions is anticipated to propel the Alzheimer’s disease biomarkers market in Europe and Asia Pacific during the forecast period. However, limited access, lack of awareness, and estimated high cost of diagnostic procedures are expected to restrain the market in Asia Pacific.
Major players operating in the global Alzheimer’s disease biomarkers market are NanoSomix, Inc., Fujirebio, Imagilys SPRL, Merck KGaA, Enzo Life Sciences, Inc., Cell Signaling Technology, Inc., QIAGEN, 23andMe, Inc., AnaSpec, Inc., and Thermo Fisher Scientific, and others.

The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.

The study is a source of reliable data on:

Market segments and sub-segments
Market trends and dynamics
Supply and demand
Market size
Current trends/opportunities/challenges
Competitive landscape
Technological breakthroughs
Value chain and stakeholder analysis

Request For TOC Report @ https://www.marketresearchreports.biz/sample/toc/8249

The regional analysis covers:

North America (U.S. and Canada)
Latin America (Mexico, Brazil, Peru, Chile, and others)
Western Europe (Germany, U.K., France, Spain, Italy, Nordic countries, Belgium, Netherlands, and Luxembourg)
Eastern Europe (Poland and Russia)
Asia Pacific (China, India, Japan, ASEAN, Australia, and New Zealand)
Middle East and Africa (GCC, Southern Africa, and North Africa)

The report has been compiled through extensive primary research (through interviews, surveys, and observations of seasoned analysts) and secondary research (which entails reputable paid sources, trade journals, and industry body databases). The report also features a complete qualitative and quantitative assessment by analyzing data gathered from industry analysts and market participants across key points in the industry’s value chain.

A separate analysis of prevailing trends in the parent market, macro- and micro-economic indicators, and regulations and mandates is included under the purview of the study. By doing so, the report projects the attractiveness of each major segment over the forecast period.

Highlights of the report:

A complete backdrop analysis, which includes an assessment of the parent market
Important changes in market dynamics
Market segmentation up to the second or third level
Historical, current, and projected size of the market from the standpoint of both value and volume
Reporting and evaluation of recent industry developments
Market shares and strategies of key players
Emerging niche segments and regional markets
An objective assessment of the trajectory of the market
Recommendations to companies for strengthening their foothold in the market

Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.

Request To PRE BOOK This Premium Report From Here @ https://www.marketresearchreports.biz/checkout?rep_id=8249&licType=S

About us

MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.

Contact

Mr. Nachiket
State Tower
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-621-2074
Website: http://www.marketresearchreports.biz/
E: sales@marketresearchreports.biz

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Alzheimers Disease Biomarkers Market Report 2018-2026 | NanoSomix, Inc., Fujirebio, Imagilys SPRL, Merck KGaA, Enzo Life Sciences here

News-ID: 1431042 • Views:

More Releases for Alzheimer’s

Increasing Global Prevalence of Alzheimer’s and Improvising Regulatory Scenari …
Alzheimer’s disease is a neurodegenerative disorder that causes slow decline in abilities such as thinking, reasoning, and routine daily activities, alongside memory loss. This may lead to planning or solving problems, poor judgment, lack of social activities, and personality and mood changes, which are considered the most common symptoms of Alzheimer’s disease. Symptoms of Alzheimer’s disease generally begin to appear in patients in their mid-sixties. As per World Alzheimer’s report,
Media Advisory: Alzheimer’s Disease Resource Center, Inc. Presents 10th Annual …
Who: Mary Ann Malack-Ragona, Executive Director/Chief Executive Officer, Alzheimer’s Disease Resource Center, Inc. (ADRC) Participating Walk for Alzheimer’s teams and individuals Mickey B, Radio Personality, WGBB Radio and Master of Ceremonies Ronald McDonald The Liberty Bells, USO troupe What: Alzheimer’s Disease Resource Center, Inc. (ADRC) is presenting its 10th Annual Old Bethpage Walk for Alzheimer’s & Mexican Fiesta. There will be an opening ceremony with Mickey B, Radio Personality, WGBB Radio, as the Master of
Home Care Assistance Partners with the Alzheimer’s Association to Promote Earl …
(Palo Alto, CA – November 29, 2011) Home Care Assistance, North America’s leading provider of in-home care for seniors, announced today that, along with companies including Genworth, Starbucks, Intel and Pfizer, they are now a Champion Partner of the Alzheimer’s Early Detection Alliance (AEDA). The AEDA is a program renowned for raising Alzheimer’s awareness and promoting early detection of the disease. As a member of this important alliance, Home
Alzheimer’s Association Long Island Announces Release of Latest Report on Alzh …
Alzheimer’s Association Long Island announced the release of the most recent report about Alzheimer’s disease. “Alzheimer’s from the Frontlines: Challenges a National Alzheimer’s Plan Must Address” provides a look into the unrelenting challenges brought on by this disease by offering insights and perspectives from individuals across the country who participated in the Alzheimer’s Association’s public input process. The Association and over 70 of its chapters hosted 132 input sessions throughout
Otava Alzheimer’s Disease Targeted Libraries
Alzheimer’s disease (AD) is a devastating and always fatal neurodegenerative disorder characterized by progressive impairment of cognitive function and emotional disturbances. Currently, more than 25 million people worldwide live with AD. But there is no cure for AD and no treatment to reverse its progression, there are medicines available that can help treat symptoms in some people with this disease. Intensive scientific research around the world brings us closer to
Alzheimer’s Association Long Island Presents Public Input Session for National …
On August 24, Alzheimer’s Association Long Island will hold a public input session to solicit views, comments and perspectives from stakeholders in the Alzheimer’s community to assist in the development of a successful National Alzheimer’s Plan. The recommendations and comments expressed during these input sessions, taking place across the country in August, will be collected and shared this fall with officials from the U.S. Department of Health and Human Services,